WHAT IS CLAIMED IS:

1. Use of a pharmaceutical composition comprising mAbBA301-cleavable linker-$MMAE_n$ and a pharmaceutically acceptable carrier, in the manufacture of a medicament for treating an Axl expressing tumor in a human subject in need of such treatment,
wherein the pharmaceutical composition is to be administered at a dose of 1.8 mg/kg of the human subject weight on days 1 and 8 every 21 days by intravenous infusion;
wherein mAbBA301 is an antibody or antibody fragment having a heavy chain variable region comprising a hcCDR1 of SEQ ID NO. 14, a hcCDR2 of SEQ ID NO. 15 and a hcCDR3 of SEQ ID NO. 16; and a light chain variable region comprising a lcCDR1 of SEQ ID NO. 17, a lcCDR2 of SEQ ID NO. 18, and a lcCDR3 of SEQ ID NO. 19; and
wherein n is an integer between 1 and 4, inclusive.

2. The use of claim 1, wherein the heavy chain variable region comprises SEQ ID NO. 20 and the light chain variable region comprises SEQ ID NO. 21.

3. The use of claim 1, wherein the cleavable linker is mc-vc-PAB.

4. The use of any one of claims 1-3, wherein the Axl expressing tumor is a sarcoma, an adenocarcinoma, or a non-small lung cell cancer.

5. The use of claim 4, wherein the Axl expressing tumor is a sarcoma.

6. The use of any one of claims 1-3, wherein a programmed death receptor-1 (PD-1) blocking antibody is to be further administered.

7. The use of any one of claims 1-3, wherein the Axl expressing tumor has a tumor membrane P score of at least 50, at least 55, at least 60, at least 65, at least 70, at least 75, at least 80, at least 85, at least 90, or at least 95.

8. The use of claim 7, wherein the Axl expressing tumor has a tumor membrane P score of at least 70.

9. The use of any one of claims 1-3, wherein a granulocyte colony stimulating factor or an analog thereof is to be further administered.

10. The use of any one of claims 1-3, wherein the pharmaceutically acceptable carrier has a pH of 6.0 and comprises 20 mM histidine-HCl, 70 mg/mL sucrose and 0.5 mg/mL polysorbate 80.

11. The use of any one of claims 1-3, wherein n equals 4.

12. Use of a pharmaceutical composition comprising mAbBA301-cleavable linker-$MMAE_n$ and a pharmaceutically acceptable carrier, in the manufacture of a medicament for treating an Axl expressing tumor in a human subject in need of such treatment,
wherein the pharmaceutical composition is to be administered at a dose of 1.8 mg/kg of the human subject weight every 21 days by intravenous infusion;
wherein mAbBA301 is an antibody or antibody fragment having a heavy chain variable region comprising a hcCDR1 of SEQ ID NO. 14, a hcCDR2 of SEQ ID NO. 15 and a hcCDR3 of SEQ ID NO. 16; and a light chain variable region comprising a lcCDR1 of SEQ ID NO. 17, a lcCDR2 of SEQ ID NO. 18 and a lcCDR3 of SEQ ID NO. 19; and
wherein n is an integer between 1 and 4, inclusive.

13. The use of claim 12, wherein the heavy chain variable region comprises SEQ ID NO. 20 and the light chain variable region comprises SEQ ID NO. 21.

14. The use of claim 12, wherein the cleavable linker is mc-vc-PAB.

15. The use of any one of claims 12-14, wherein the Axl expressing tumor is a sarcoma, an adenocarcinoma, or a non-small lung cell cancer.

16. The use of claim 15, wherein the Axl expressing tumor is a sarcoma.

17. The use of any one of claims 12-14, wherein a programmed death receptor-1 (PD-1) blocking antibody is to be further administered.

18. The use of any one of claims 12-14, wherein the Axl expressing tumor has a tumor membrane P score of at least 50, at least 55, at least 60, at least 65, at least 70, at least 75, at least 80, at least 85, at least 90, or at least 95.

19. The use of claim 18, wherein the Axl expressing tumor has a tumor membrane P score of at least 70.

20. The use of any one of claims 12-14, wherein a granulocyte colony stimulating factor or an analog thereof is to be further administered.

21. The use of any one of claims 12-14, wherein the pharmaceutically acceptable carrier has a pH of 6.0 and comprises 20 mM histidine-HCl, 70 mg/mL sucrose and 0.5 mg/mL polysorbate 80.

22. The use of any one of claims 12-14, wherein n equals 4.